Regeneron Pharma (REGN) Guides FY12 Eylea Sales
REGN Hot Sheet
Financial Fact:Total other income (expense): -10.55M
Today's EPS Names:
TARO, BRLI, TLB, More
Regeneron Pharma (Nasdaq: REGN) sees FY12 Eylea sales in the US of $250-$300 million.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Jiayuan.com (DATE) Reports In-Line Q1 EPS of 5c; Guides Q2 Revs
- Pandora (P) Blows Up Expectations as Listener Hours Rip; Guides FY13 Ahead of Views
Create E-mail Alert Related Categories
GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
